Another retrospective study (n = 117 patients) evaluated the prognostic impact of the presence of a double hit (defined as rearrangements of MYC and BCL2 and/or BCL6) or double expression of MYC and BCL2 on the outcomes of ASCT in patients with R/R DLBCL. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.